A review of 260 epidemiological studies published in the last 5 years to survey the current state of evidence on the burden of liver disease in Europe and its causes.
What are you doing to promote Hepatitis Awareness Day?
The European Association for the Study of the Liver (EASL) has joined other members of the European Chronic Disease Alliance (ECDA) in signing an Open Letter to President Barroso. The letter expresses ECDA’s concern over the lack of political will from the leadership of the European Union with regards to chronic diseases.
Now 3827 members from 106 countries
EU Policy statements

EASL is pushing for EU policy development in areas relevant to liver disease, such as public health, research, communicable diseases (viral hepatitis), nutrition and obesity, alcohol, cancer, rare diseases, organ donation and transplantation to take liver disease into account.

On 24 May 2010, the 63rd World Health Assembly, brought together Health Ministers and senior health officials from the World Health Organization (WHO) Member States and concluded business with delegates adopting resolutions on a variety of global health issues. The details of two of the resolutions of particular interest to EASL, can be found below:

* Resolution WHA63.13 on Global strategy to reduce the harmful use of alcohol

* Resolution WHA63.18 on Viral hepatitis

On 18 October, MEPs Marisa Matias (PT, GUE), Jo Leinen (DE, S&D), Michèle Rivasi (FR, Greens), Herbert Reul (DE, EPP) and Antonyia Parvanova (BG, ALDE) tabled a cross-party group Written Declaration on ‘the need for increased coordination of cancer research in the European Union’. The Written Declaration calls on the European Commission and EU member states to enhance cooperation and coordination on cancer research and promote transnational research in the context of the European Partnership for Action Against Cancer. The Written Declaration also calls for partnerships with patient organisations. For the Written Declaration to be adopted, 369 MEP signatures are needed by 3 February 2011.

Learn more about EASL's advocacy activities here. For an outline of each policy area, how each is relevant to liver disease and how EASL has positioned itself in the debate, click on the different hepatocytes below.

FLASH
DO NOT DELETE
OR MODIFY THIS GREY BOX!